-
Reply: The new ERS/ATS standards on lung function test interpretation: some extant limitations Eur. Respir. J. (IF 33.795) Pub Date : 2022-08-10 Sanja Stanojevic, David A. Kaminsky, Martin Miller, Bruce Thompson
We would like to thank J.A. Neder for his thoughtful correspondence and critical review of the updated ERS/ATS technical statement on pulmonary function test interpretation [1]. As the updated technical document focuses on physiological interpretation of pulmonary function tests, we welcome the discussion on how to incorporate these updated standards into clinical practice.
-
Treatment outcomes of multidrug-resistant tuberculosis with chronic kidney/liver disease Eur. Respir. J. (IF 33.795) Pub Date : 2022-08-10 Chiwook Chung, Jung Eun Shin, Doosoo Jeon, Hyungseok Kang, Jae-Joon Yim, Kyung-Wook Jo, Tae Sun Shim
Each year, ~500 000 people worldwide suffer from rifampin-resistant tuberculosis (RR-TB) or multidrug-resistant tuberculosis (MDR-TB; resistance to both rifampin and isoniazid) [1]. Bedaquiline and delamanid are newly developed anti-TB drugs and their efficacies in the treatment of MDR/RR-TB have been well documented in both randomised controlled trials [2, 3] and cohort studies [4, 5]. As these new
-
Cystic fibrosis transmembrane conductance regulator (CFTR): a missing link between smoking and chronic airway diseases? Eur. Respir. J. (IF 33.795) Pub Date : 2022-08-10 Pierre-Régis Burgel, Nicolas Roche
Mucus abnormalities play important roles in the development and/or evolution of most, if not all, airway diseases. The airway mucus is both a crucial component of the airway's mechanical defence mechanisms against irritants and microorganisms, and a marker of airway injury: its composition is influenced by various pathophysiological mechanisms involved in acute and chronic airway diseases, including
-
Update June 2022: management of hospitalised adults with coronavirus disease 2019 (COVID-19): a European Respiratory Society living guideline Eur. Respir. J. (IF 33.795) Pub Date : 2022-08-10 Nicolas Roche, Megan L. Crichton, Pieter C. Goeminne, Bin Cao, Marc Humbert, Michal Shteinberg, Katerina M. Antoniou, Charlotte Suppli Ulrik, Helen Parks, Chen Wang, Thomas Vandendriessche, Jieming Qu, Daiana Stolz, Christopher Brightling, Tobias Welte, Stefano Aliberti, Anita K. Simonds, Thomy Tonia, James D. Chalmers
Since the identification of SARS-CoV-2 at the end of 2019, the coronavirus disease 2019 (COVID-19) pandemic has affected more than 410 million people worldwide and killed almost 6 million [1, 2]. The predecessors of COVID-19, i.e. the SARS (severe acute respiratory syndrome) and MERS (Middle East respiratory syndrome) outbreaks, had been relatively self-limiting, preventing clinicians and researchers
-
Improving interferon-γ release assay interpretation: are IP-10 and MIG the solution? Eur. Respir. J. (IF 33.795) Pub Date : 2022-08-10 Francesca Saluzzo, Claudia M. Denkinger, Daniela M. Cirillo
It is a bumpy road, to develop a tuberculosis infection (TBI) test with the capability of predicting progression to active tuberculosis (TB). As a gold standard for TBI diagnosis with these characteristics is still missing, tuberculin skin tests (TSTs) and the interferon- (IFN-) release assays (IGRAs), including QuantiFERON-TB Gold Plus (QFT-plus) and T-SPOT.TB, remain the main tests used to identify
-
The new ERS/ATS standards on lung function test interpretation: some extant limitations Eur. Respir. J. (IF 33.795) Pub Date : 2022-08-10 J. Alberto Neder
Pulmonary function tests (PFTs) remain of foremost relevance to the management of patients with respiratory diseases. The recently published European Respiratory Society (ERS)/American Thoracic Society (ATS) document on testing interpretation is therefore poised to influence the way pulmonologists teach, describe and quantify respiratory physiological impairment [1]. A careful appraisal of its main
-
“Management of hospitalised adults with coronavirus disease 2019 (COVID-19): a European Respiratory Society living guideline.” James D. Chalmers, Megan L. Crichton, Pieter C. Goeminne, et al. Eur Respir J 2021; 57: 2100048. Eur. Respir. J. (IF 33.795) Pub Date : 2022-08-10 European Respiratory Society
The ERS living guideline document regarding the management of hospitalised adults with COVID-19 has been updated and republished.
-
The carbon footprint of respiratory treatments in Europe and Canada: an observational study from the CARBON programme Eur. Respir. J. (IF 33.795) Pub Date : 2022-08-10 Christer Janson, Ekaterina Maslova, Alexander Wilkinson, Erika Penz, Alberto Papi, Nigel Budgen, Claus F. Vogelmeier, Maciej Kupczyk, John Bell, Andrew Menzies-Gow
Climate change represents a global challenge and nations are increasingly looking to decarbonise their economies by developing roadmaps for reducing greenhouse gas (GHG) emissions in accordance with international treaties, such as the Paris Agreement [1]. As the healthcare sector remains a key contributor to GHG emissions [2], an examination of the global carbon footprint of its operations and treatment
-
Biomarkers to identify Mycobacterium tuberculosis infection among borderline QuantiFERON results Eur. Respir. J. (IF 33.795) Pub Date : 2022-08-10 Jonathan W. Uzorka, Jaap A. Bakker, Krista E. van Meijgaarden, Eliane M.S. Leyten, Nathalie M. Delfos, David J. Hetem, Jos Kerremans, Mieke Zwarts, Sandra Cozijn, Tom H.M. Ottenhoff, Simone A. Joosten, Sandra M. Arend
Background Screening for tuberculosis (TB) infection often includes QuantiFERON-TB Gold Plus (QFT) testing. Previous studies showed that two-thirds of patients with negative QFT results just below the cut-off, so-called borderline test results, nevertheless had other evidence of TB infection. This study aimed to identify a biomarker profile by which borderline QFT results due to TB infection can be
-
Flavonoid intakes inversely associate with COPD in smokers Eur. Respir. J. (IF 33.795) Pub Date : 2022-08-10 Nicola P. Bondonno, Benjamin H. Parmenter, Frederik Dalgaard, Kevin Murray, Daniel Bech Rasmussen, Cecilie Kyrø, Aedin Cassidy, Catherine P. Bondonno, Joshua R. Lewis, Kevin D. Croft, Gunnar Gislason, Augustin Scalbert, Anne Tjønneland, Kim Overvad, Anja Olsen, Jonathan M. Hodgson
Introduction Higher flavonoid intakes are beneficially associated with pulmonary function parameters; however, their association with chronic obstructive pulmonary disease (COPD) is unknown. This study aimed to examine associations between intakes of 1) total flavonoids, 2) flavonoid subclasses and 3) major flavonoid compounds with incident COPD in participants from the Danish Diet, Cancer and Health
-
Effect of interleukin-6 receptor antagonists in critically ill adult patients with COVID-19 pneumonia: two randomised controlled trials of the CORIMUNO-19 Collaborative Group Eur. Respir. J. (IF 33.795) Pub Date : 2022-08-10 Olivier Hermine, Xavier Mariette, Raphael Porcher, Matthieu Resche-Rigon, Pierre-Louis Tharaux, Philippe Ravaud
Background Our objective was to determine whether anti-interleukin (IL)-6 receptors improve outcomes of critically ill patients with coronavirus disease 2019 (COVID-19) pneumonia. We report on two cohort-embedded, investigator-initiated, multicentre, open-label, Bayesian randomised controlled clinical trials. Methods Patients were randomly assigned to receive either usual care (UC) or UC+tocilizumab
-
Topical therapy with negative allosteric modulators of the calcium-sensing receptor (calcilytics) for the management of asthma: the beginning of a new era? Eur. Respir. J. (IF 33.795) Pub Date : 2022-08-10 Daniela Riccardi, Jeremy P.T. Ward, Polina L. Yarova, Luke J. Janssen, Tak Hong Lee, Sun Ying, Chris J. Corrigan
In this review article we present the evidence to date supporting the role of the calcium-sensing receptor (CaSR) as a key, pluripotential molecular trigger for asthma and speculate on the likely benefits of topical therapy of asthma with negative allosteric modulators of the CaSR: calcilytics.
-
CFTR variants are associated with chronic bronchitis in smokers Eur. Respir. J. (IF 33.795) Pub Date : 2022-08-10 Aabida Saferali, Dandi Qiao, Wonji Kim, Karen Raraigh, Hara Levy, Alejandro A. Diaz, Garry R. Cutting, Michael H. Cho, Craig P. Hersh
Introduction Loss-of-function variants in both copies of the cystic fibrosis transmembrane conductance regulator (CFTR) gene cause cystic fibrosis (CF); however, there is evidence that reduction in CFTR function due to the presence of one deleterious variant can have clinical consequences. Here, we hypothesise that CFTR variants in individuals with a history of smoking are associated with chronic obstructive
-
A step forward for an intermediate cystic fibrosis population Eur. Respir. J. (IF 33.795) Pub Date : 2022-08-04 Susan E. Birket
Cystic fibrosis (CF) is a life-long and life-shortening disease, best treated with early interventions to prevent complications across multiple organs and to extend the lifespan of this population. In the USA and Europe, the diagnosis of CF occurs primarily through newborn screening [1]. Newborns with two defective copies of the cystic fibrosis transmembrane conductance regulator (Cftr) gene have elevated
-
Unbowed, unbent, unbroken: predicting pulmonary hypertension using echocardiography Eur. Respir. J. (IF 33.795) Pub Date : 2022-08-04 Mariëlle C. van de Veerdonk, Anton Vonk-Noordegraaf, Jean-Luc Vachiery
During the first meeting of the World Health Organization (WHO) in 1973, pulmonary hypertension (PH) was defined as mean pulmonary artery pressure (mPAP) ≥25 mmHg measured by right heart catheterisation [1]. This criterion was chosen arbitrarily and was founded on the premise that mPAP at rest in a supine position does not exceed 15 mmHg 2]. In 2009, the landmark paper of Kovacs et al. [3] provided
-
Reclassifying inconclusive diagnosis for cystic fibrosis with new generation sweat test Eur. Respir. J. (IF 33.795) Pub Date : 2022-08-04 Thao Nguyen-Khoa, Aurélie Hatton, David Drummond, Laura Aoust, Joël Schlatter, Clémence Martin, Sophie Ramel, Sébastien Kiefer, Elsa Gachelin, Nathalie Stremler, Laure Cosson, Asma Gabsi, Natascha Remus, Myriam Benhamida, Alice Hadchouel, Isabelle Fajac, Anne Munck, Emmanuelle Girodon, Isabelle Sermet-Gaudelus
The biological diagnosis of cystic fibrosis (CF) is based on a sweat chloride (Cl–) concentration (SCC) ≥60 mmol·L–1 and/or the identification of two allelic CF-causing variants [1]. Diagnosis of CF can be challenging in subjects with intermediate SCC between 30 and 59 mmol·L–1 and only one CF-causing variant detected.
-
Outcomes of cirrhotic patients with pre-capillary pulmonary hypertension and pulmonary vascular resistance between 2 and 3 Wood Units Eur. Respir. J. (IF 33.795) Pub Date : 2022-08-04 Marie Caroline Certain, Audrey Baron, Matthieu Turpin, Nathan Ebstein, Athénaïs Boucly, Antoine Beurnier, Mitja Jevnikar, Anne Roche, Sophia Keddache, Sophie Bulifon, Andrei Seferian, Xavier Jaïs, David Montani, Marc Humbert, Olivier Sitbon, Laurent Savale
Portopulmonary hypertension (PoPH) is a subtype of pulmonary arterial hypertension (PAH) complicating the course of portal hypertension [1, 2]. Similar to other causes of PAH, PoPH is characterised by a progressive structural and functional remodelling of small pulmonary arteries leading to pre-capillary pulmonary hypertension defined by a mean pulmonary artery pressure (mPAP) ≥25 mmHg, normal pulmonary
-
Refined risk stratification in pulmonary arterial hypertension and timing of lung transplantation Eur. Respir. J. (IF 33.795) Pub Date : 2022-08-04 Karen M. Olsson, Manuel J. Richter, Jan C. Kamp, Henning Gall, Hossein-Ardeshir Ghofrani, Jan Fuge, Ralf Ewert, Marius M. Hoeper
In patients with pulmonary arterial hypertension (PAH) presenting with progressive disease despite optimised medical therapy, lung transplantation remains an important treatment option [1–3]. Current guidelines recommend assessing the individual mortality risk regularly using a three-stratum model to determine whether patients are at low, intermediate or high risk of death [1, 2].
-
Echocardiographic probability of pulmonary hypertension: a validation study Eur. Respir. J. (IF 33.795) Pub Date : 2022-08-04 Michele D'Alto, Marco Di Maio, Emanuele Romeo, Paola Argiento, Ettore Blasi, Alessandro Di Vilio, Gaetano Rea, Antonello D'Andrea, Paolo Golino, Robert Naeije
Background According to current guidelines, the diagnosis of pulmonary hypertension (PH) relies on echocardiographic probability followed by right heart catheterisation (RHC). How echocardiography predicts PH recently redefined by mean pulmonary arterial pressure (mPAP) >20 mmHg instead of ≥25 mmHg and pulmonary vascular disease defined by pulmonary vascular resistance (PVR) ≥3 or >2 WU has not been
-
Effect of high versus low dose of dexamethasone on clinical worsening in patients hospitalised with moderate or severe COVID-19 pneumonia: an open-label, randomised clinical trial Eur. Respir. J. (IF 33.795) Pub Date : 2022-08-04 Manuel Taboada, Nuria Rodríguez, Pablo Manuel Varela, María Teresa Rodríguez, Romina Abelleira, Amara González, Ana Casal, José Antonio Díaz Peromingo, Adriana Lama, María Jesús Domínguez, Carlos Rábade, Emilio Manuel Páez, Vanessa Riveiro, Hadrián Pernas, María del Carmen Beceiro, Valentín Caruezo, Alberto Naveira, Agustín Cariñena, Teresa Cabaleiro, Ana Estany-Gestal, Irene Zarra, Antonio Pose, Luis
Background Low-dose dexamethasone demonstrated clinical improvement in patients with coronavirus disease 2019 (COVID-19) needing oxygen therapy; however, evidence on the efficacy of high-dose dexamethasone is limited. Methods We performed a randomised, open-label, controlled trial involving hospitalised patients with confirmed COVID-19 pneumonia needing oxygen therapy. Patients were randomly assigned
-
Impact of hepatopulmonary syndrome in liver transplantation candidates and the role of angiogenesis Eur. Respir. J. (IF 33.795) Pub Date : 2022-08-04 Steven M. Kawut, Michael J. Krowka, Kimberly A. Forde, Nadine Al-Naamani, Karen L. Krok, Mamta Patel, Carlo R. Bartoli, Margaret Doyle, Jude Moutchia, Grace Lin, Jae K. Oh, Carl D. Mottram, Paul D. Scanlon, Michael B. Fallon
Background Hepatopulmonary syndrome affects 10–30% of patients with cirrhosis and portal hypertension. We evaluated the serum angiogenic profile of hepatopulmonary syndrome and assessed the clinical impact of hepatopulmonary syndrome in patients evaluated for liver transplantation. Methods The Pulmonary Vascular Complications of Liver Disease 2 study was a multicentre, prospective cohort study of adults
-
European Respiratory Society statement on long COVID follow-up Eur. Respir. J. (IF 33.795) Pub Date : 2022-08-04 Katerina M. Antoniou, Eirini Vasarmidi, Anne-Marie Russell, Claire Andrejak, Bruno Crestani, Marion Delcroix, Anh Tuan Dinh-Xuan, Venerino Poletti, Nicola Sverzellati, Michele Vitacca, Martin Witzenrath, Thomy Tonia, Antonio Spanevello
Patients diagnosed with coronavirus disease 2019 (COVID-19) associated with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection frequently experience symptom burden post-acute infection or post-hospitalisation. We aimed to identify optimal strategies for follow-up care that may positively impact the patient's quality of life (QoL). A European Respiratory Society (ERS) Task Force
-
Location of eosinophils in the airway wall is critical for specific features of airway hyperresponsiveness and T2 inflammation in asthma Eur. Respir. J. (IF 33.795) Pub Date : 2022-08-04 Taha Al-Shaikhly, Ryan C. Murphy, Andrew Parker, Ying Lai, Matthew C. Altman, Megan Larmore, William A. Altemeier, Charles W. Frevert, Jason S. Debley, Adrian M. Piliponsky, Steven F. Ziegler, Michael C. Peters, Teal S. Hallstrand
Background Eosinophils are implicated as effector cells in asthma, but the functional implications of the precise location of eosinophils in the airway wall is poorly understood. We aimed to quantify eosinophils in the different compartments of the airway wall and associate these findings with clinical features of asthma and markers of airway inflammation. Methods In this cross-sectional study, we
-
The association of lung function and pulmonary vasculature volume with cardiorespiratory fitness in the community Eur. Respir. J. (IF 33.795) Pub Date : 2022-08-04 Jenna McNeill, Ariel Chernofsky, Matthew Nayor, Farbod N. Rahaghi, Raul San Jose Estepar, George Washko, Andrew Synn, Ramachandran S. Vasan, George O'Connor, Martin G. Larson, Jennifer E. Ho, Gregory D. Lewis
Background Cardiorespiratory fitness is not limited by pulmonary mechanical reasons in the majority of adults. However, the degree to which lung function contributes to exercise response patterns among ostensibly healthy individuals remains unclear. Methods We examined 2314 Framingham Heart Study participants who underwent cardiopulmonary exercise testing (CPET) and pulmonary function testing. We investigated
-
Vulnerability to acid reflux of the airway epithelium in severe asthma Eur. Respir. J. (IF 33.795) Pub Date : 2022-08-04 Jeanne-Marie Perotin, Gabrielle Wheway, Kamran Tariq, Adnan Azim, Robert A. Ridley, Jonathan A. Ward, James P.R. Schofield, Clair Barber, Peter Howarth, Donna E. Davies, Ratko Djukanovic
Background Severe asthma is associated with multiple comorbidities, including gastro-oesophageal reflux disease (GORD), which can contribute to exacerbation frequency and poor quality of life. Since epithelial dysfunction is an important feature in asthma, we hypothesised that in severe asthma the bronchial epithelium is more susceptible to the effects of acid reflux. Methods We developed an in vitro
-
The Roughton–Forster equation for pulmonary diffusion: how it happened Eur. Respir. J. (IF 33.795) Pub Date : 2022-07-28 Mike Hughes
The transfer factor of the lung for carbon monoxide (TLCO) and spirometry are our two most valued tests in functional assessment. The understanding of the physiology underpinning TLCO (or DLCO) owes much to Robert Forster's research, including the formulation of the Roughton–Forster equation [1], the topic of this editorial. His other research involved oxygen and CO2 exchange, the role of carbonic
-
Blood trihalomethane concentrations and lung function in US adolescents: a nationally representative cross-sectional study Eur. Respir. J. (IF 33.795) Pub Date : 2022-07-28 Yang Sun, Yi-Xin Wang, Vicente Mustieles, Yu Zhang, Xiong-Fei Pan, Carmen Messerlian
Lung function in adolescence is a powerful marker of overall health during adulthood and has been associated with the incidence of respiratory, cardiovascular and metabolic comorbidities in later life [1]. To improve early intervention, the identification of risk factors that may predispose children and adolescents towards poor lung function is urgently needed.
-
We need to understand why viral infections lead to acute asthma Eur. Respir. J. (IF 33.795) Pub Date : 2022-07-28 Peter A.B. Wark
Acute exacerbations of asthma are an important and unmet asthma need [1], responsible for considerable morbidity and economic cost, across all age groups [2]. The most common triggers are acute viral infections and seasonal allergen exposure [1, 3]. This close epidemiological relationship is demonstrated by the fact that the prevalence of endemic rhinovirus is the commonest predictor of acute asthma
-
Phenotype and severity of asthma determines bronchial epithelial immune responses to a viral mimic Eur. Respir. J. (IF 33.795) Pub Date : 2022-07-28 Celeste Porsbjerg, Juan Jose Nieto-Fontarigo, Samuel Cerps, Sangheeta Ramu, Mandy Menzel, Morten Hvidtfeldt, Alexander Silberbrandt, Laurits Frøssing, Ditte Klein, Asger Sverrild, Lena Uller
Background Asthma is characterised by an aggravated immune response to respiratory viral infections. This phenomenon is a clinically well-recognised driver of acute exacerbations, but how different phenotypes of asthma respond immunologically to viruses is unclear. Objectives To describe the association between different phenotypes and severity of asthma and bronchial epithelial immune responses to
-
Methods for the assessment of human airway ciliary function Eur. Respir. J. (IF 33.795) Pub Date : 2022-07-28 Claire L. Jackson, Mathieu Bottier
Airway ciliary function analysis underpins PCD diagnostics and ex vivo / in vitro mucociliary clearance studies. It is an important measure of airway culture model integrity in health and after microbial/viral infections or airway drug therapies.
-
Fine particulate matter components and interstitial lung disease in rheumatoid arthritis Eur. Respir. J. (IF 33.795) Pub Date : 2022-07-28 Naizhuo Zhao, Ziyad Al-Aly, Boyang Zheng, Aaron van Donkelaar, Randall V. Martin, Christian A. Pineau, Sasha Bernatsky
Background Exposure to ambient fine particulate matter with an aerodynamic diameter <2.5 μg·m–3 (PM2.5) is a risk factor for pulmonary and systemic autoimmune diseases; however, evidence on which PM2.5 chemical components are more harmful is still scant. Our goal is to investigate potential associations between major PM2.5 components and interstitial lung disease (ILD) onset in rheumatoid arthritis
-
Mycobacterium tuberculosis-specific CD4 T-cell scoring discriminates tuberculosis infection from disease Eur. Respir. J. (IF 33.795) Pub Date : 2022-07-28 Andrej Mantei, Tim Meyer, Mariana Schürmann, Christiane Beßler, Harald Bias, David Krieger, Torsten Bauer, Petra Bacher, Johannes Helmuth, Hans-Dieter Volk, Dirk Schürmann, Alexander Scheffold, Christian Meisel
Background Rapid and reliable diagnostic work-up of tuberculosis (TB) remains a major healthcare goal. In particular, discrimination of TB infection from TB disease with currently available diagnostic tools is challenging and time consuming. This study aimed at establishing a standardised blood-based assay that rapidly and reliably discriminates TB infection from TB disease based on multiparameter
-
Improved ventilatory efficiency to evidence haemodynamic improvement after balloon pulmonary angioplasty in chronic thromboembolic pulmonary hypertension. Eur. Respir. J. (IF 33.795) Pub Date : 2022-07-27 Simon Madoun,Nicolas Piliero,Alicia Guillien,Muriel Salvat,Frédéric Thony,Mathieu Finas,Caroline Augier,Hélène Bouvaist,Bruno Degano
-
Lung allograft transbronchial cryobiopsy for critical ventilated patients: a randomised trial. Eur. Respir. J. (IF 33.795) Pub Date : 2022-07-26 Karina Loor,Mario Culebras,Irene Sansano,Antonio Álvarez,Judith Sacanell,Marina García-de-Acilu,Cristina Berastegui,Eva Polverino,David Clofent,Javier de Gracia
RATIONALE Transbronchial lung cryobiopsy is an emerging technique for diagnosing pulmonary rejection. However, no prospective studies of critically ill lung transplant recipients who require mechanical ventilation in the intensive care unit have been performed. OBJECTIVES AND METHODS From March 2017 to January 2020, we performed a prospective, randomised, comparative study to assess the diagnostic
-
Adrenal function recovery after durable OCS-sparing with benralizumab in the PONENTE study. Eur. Respir. J. (IF 33.795) Pub Date : 2022-07-26 Andrew Menzies-Gow,Mark Gurnell,Liam G Heaney,Jonathan Corren,Elisabeth H Bel,Jorge Maspero,Timothy Harrison,David J Jackson,David Price,Njira Lugogo,James Kreindler,Annie Burden,Alex de Giorgio-Miller,Sarai Faison,Kelly Padilla,Ubaldo J Martin,Esther Garcia Gil,
Oral corticosteroid dependence among patients with severe eosinophilic asthma can cause adverse outcomes, including adrenal insufficiency. PONENTE's oral corticosteroid-reduction phase showed that, following benralizumab initiation, 91.5% of patients eliminated corticosteroids or achieved a final dosage ≤5 mg·day-1 (median, 0.0 mg [range, 0.0-40.0]).The maintenance phase assessed the durability of
-
Air pollution, SARS-CoV-2 incidence and COVID-19 mortality in Rome - a longitudinal study. Eur. Respir. J. (IF 33.795) Pub Date : 2022-07-26 Federica Nobile,Paola Michelozzi,Carla Ancona,Giovanna Cappai,Giulia Cesaroni,Marina Davoli,Mirko Di Martino,Emanuele Nicastri,Enrico Girardi,Alessia Beccacece,Paola Scognamiglio,Chiara Sorge,Francesco Vairo,Massimo Stafoggia
-
Impact of COVID-19 social distancing measures on lung transplant recipients: decline in overall respiratory virus infections is associated with stabilisation of lung function. Eur. Respir. J. (IF 33.795) Pub Date : 2022-07-26 Auke E S de Zwart,Annelies Riezebos-Brilman,Gerton A Lunter,Ewald C U Neerken,Coretta C van Leer-Buter,Jan-Willem C Alffenaar,Anna P van Gemert,Michiel E Erasmus,Christiaan T Gan,Huib A M Kerstjens,Judith M Vonk,Erik A M Verschuuren
BACKGROUND COVID-19 social distancing measures led to a dramatic decline in non-COVID respiratory virus (RV) infections, providing a unique opportunity to study their impact on annual FEV1 decline, episodes of temporary drop in lung function (TDLF) suggestive of infection and chronic lung allograft dysfunction (CLAD) in lung transplant recipients (LTR). METHODS All FEV1 values of LTR transplanted between
-
COVID-19 drug research and the cohort multiple randomised controlled trial design. Eur. Respir. J. (IF 33.795) Pub Date : 2022-07-26 Raphaël Porcher,Philippe Ravaud,Matthieu Resche-Rigon,Pierre Louis Tharaux,Xavier Mariette,Olivier Hermine
-
Early life respiratory infections and pre-adult asthma: could there be an interaction and differential misclassification? Eur. Respir. J. (IF 33.795) Pub Date : 2022-07-26 Jennifer L Perret,Shyamali C Dharmage,Dinh S Bui
-
Immunomodulation and endothelial barrier protection mediate the association between oral imatinib and mortality in hospitalised COVID-19 patients. Eur. Respir. J. (IF 33.795) Pub Date : 2022-07-26 Justin de Brabander,Erik Duijvelaar,Job R Schippers,Patrick J Smeele,Hessel Peters-Sengers,Jan Willem Duitman,Jurjan Aman,Harm J Bogaard,Tom van der Poll,Lieuwe D J Bos,
INTRODUCTION Imatinib reduced 90-day mortality in hospitalised COVID-19 patients in a recent clinical trial, but the biological effects that cause improved clinical outcomes are unknown. We aimed to determine the biological changes elicited by imatinib in patients with COVID-19, and what baseline biological profile moderates the effect of imatinib. METHODS Secondary analysis of a randomised, double-blind
-
Green and blue spaces and lung function in the Generation XXI cohort: a life course approach. Eur. Respir. J. (IF 33.795) Pub Date : 2022-07-26 Diogo Queiroz Almeida,Inês Paciência,Carla Moreira,João Cavaleiro Rufo,André Moreira,Ana Cristina Santos,Henrique Barros,Ana Isabel Ribeiro
Exposure to natural environments may affect respiratory health. This study examined the association of the exposure to green and blue spaces with lung function in children, and assessed the mediation effect of air pollution and physical activity.The study used data from the Generation XXI, a population-based birth cohort from the Porto Metropolitan Area (Portugal). Residential Normalised Difference
-
Increasing physical activity in severe asthma: a systematic review and meta-analysis. Eur. Respir. J. (IF 33.795) Pub Date : 2022-07-26 Rebecca F McLoughlin,Vanessa L Clark,Paola D Urroz,Peter G Gibson,Vanessa M McDonald
INTRODUCTION/AIM Physical inactivity is common in asthma and is recognised as an important modifiable risk for poor clinical outcomes such as impaired asthma control and health-related quality of life (HRQoL). Despite evidence supporting the role of physical activity (PA) in reducing the risk of these outcomes, little is known about optimal interventions for increasing PA in those with severe disease
-
Detection of COPD in the SUMMIT Study Lung Cancer Screening Cohort using Symptoms and Spirometry. Eur. Respir. J. (IF 33.795) Pub Date : 2022-07-26 Sophie Tisi,Jennifer L Dickson,Carolyn Horst,Samantha L Quaife,Helen Hall,Priyam Verghese,Kylie Gyertson,Vicky Bowyer,Claire Levermore,Anne-Marie Mullin,Jonathan Teague,Laura Farrelly,Arjun Nair,Anand Devaraj,Allan Hackshaw,John R Hurst,Sam M Janes,
BACKGROUND COPD is a major comorbidity in lung cancer screening (LCS) cohorts, with a high prevalence of undiagnosed COPD. Combining symptom assessment with spirometry in this setting may enable earlier diagnosis of clinically significant COPD and facilitate increased understanding of lung cancer risk in COPD. In this study, we wished to understand the prevalence, severity, clinical phenotype and lung
-
Risk assessment of systemic sclerosis-associated pulmonary arterial hypertension: cardiac index versus stroke volume index. Eur. Respir. J. (IF 33.795) Pub Date : 2022-07-26 Hussein J Hassan,Mario Naranjo,Brigitte Kazzi,Traci Housten-Harris,Steven Hsu,Aparna Balasubramanian,Catherine E Simpson,Rachel L Damico,Todd M Kolb,Stephen C Mathai,Paul M Hassoun
-
Reply to: "Early-life respiratory infections and pre-adult asthma: could there be an interaction and differential misclassification?" Eur. Respir. J. (IF 33.795) Pub Date : 2022-07-26 Evelien R van Meel,Liesbeth Duijts
-
Reference equations for evaluation of spirometry function tests in South Asia, and amongst South Asians living in other countries. Eur. Respir. J. (IF 33.795) Pub Date : 2022-07-26 Wei Yee Leong,Ananya Gupta,Mehedi Hasan,Sara Mahmood,Samreen Siddiqui,Sajjad Ahmed,Ian Y Goon,Marie Loh,Theresia H Mina,Benjamin Lam,Yik Weng Yew,Joanne Ngeow,Jimmy Lee,Eng Sing Lee,Elio Riboli,Paul Elliott,Geak Poh Tan,Sanjay H Chotirmall,Ananda R Wickremasinghe,Jaspal S Kooner,Khadija I Khawaja,Prasad Katulanda,Malay K Mridha,Sujeet Jha,Anjana Ranjit M,Guha Pradeepa,Anuradhani Kasturiratne,John C
BACKGROUND There is little data to accurate interpretation of spirometry data in South Asia, a major global region with high reported burden for chronic respiratory disease. METHOD We measured lung function in 7,453 healthy men and women aged over 18 years, from Bangladesh, North India, South India, Pakistan and Sri Lanka, as part of the South Asia Biobank study. We first assessed the accuracy of existing
-
COVID-19 drug research and the cohort multiple randomised controlled trial design. Eur. Respir. J. (IF 33.795) Pub Date : 2022-07-26 Rafael Dal-Ré
-
Reply: Ex vivo SOCS3 gene responsiveness to alarmins in eosinophils of mepolizumab-treated patients is as yet of unknown biological significance Eur. Respir. J. (IF 33.795) Pub Date : 2022-07-21 Glenn Van Hulst, Joseph Jorssen, Nathalie Jacobs, Monique Henket, Renaud Louis, Florence Schleich, Fabrice Bureau, Christophe J. Desmet
We thank S. Couillard for his interesting comments related to our publication on the effects of interleukin (IL)-5 deficiency on the transcriptome of residual eosinophils of Il5-deficient mice and mepolizumab-treated patients [1]. We indeed document stronger upregulation of the expression of the SOCS3 gene following stimulation with IL-33 ex vivo that is conserved between eosinophils from mepolizumab-treated
-
The alarmin(g) effect of interleukin-5 blockade on residual eosinophil function is of clinical consequence Eur. Respir. J. (IF 33.795) Pub Date : 2022-07-21 Simon Couillard
Congratulations to Van Hulst et al. [1] regarding their article on the influence of interleukin (IL)-5 blockade on blood eosinophils in severe asthma. In their discussion, the authors state that it is unclear whether increased stimulation-induced expression of suppressor of cytokine signalling-3 (SOCS3) in eosinophils in IL-5-depleted conditions is of clinical consequence. However, their data can be
-
Securing the chest tube: in search of the elusive solution Eur. Respir. J. (IF 33.795) Pub Date : 2022-07-21 Srinivas R. Mummadi, José M. Porcel
Chest tubes are frequently indicated for removing accumulated air or fluid from the pleural space due to a variety of conditions, such as pneumothorax, empyema, haemothorax or malignant pleural effusions for which a bedside pleurodesis procedure is planned [1]. Small-bore chest tubes (SBCT), defined as those having an outer diameter of 14 Fr or less, are recommended as a first-line approach in most
-
Controlling chronic respiratory diseases in Finland from 1996 to 2018 Eur. Respir. J. (IF 33.795) Pub Date : 2022-07-21 Tiina Mattila, Marina Erhola, Tuula Vasankari, Sanna Toppila-Salmi, Fredrik Herse, Riikka-Leena Leskelä, Vesa Jormanainen, Anelma Lammi, Tari Haahtela
From the 1990s, five national programmes were carried out in Finland to respond to respiratory health challenges [1–6]. Previous experience from tuberculosis facilitated the launch of other initiatives. The programmes were implemented in the national public healthcare. Importantly, professional associations, non-governmental patient organisations (NGOs) and pharmacies contributed to the change of clinical
-
Benefit of monoclonal antibodies in early treatment of COVID-19 after lung transplantation: a retrospective analysis in two centres Eur. Respir. J. (IF 33.795) Pub Date : 2022-07-21 Jens Gottlieb, Martin Kolditz, Nils Gade, Tobias Welte, Nikolaus Kneidinger
Transplant recipients are at risk for poor outcomes from coronavirus disease 2019 (COVID-19) due to frequent medical comorbidities and presence of immunosuppression. Observational cohort studies suggest that patients after lung transplantation (LTx) with COVID-19 may have higher mortality in comparison to other solid organ transplant recipients. In a US retrospective analysis in the beginning of 2020
-
Health effects of exposure to residential air pollution in patients with pulmonary arterial hypertension: a cohort study in Belgium Eur. Respir. J. (IF 33.795) Pub Date : 2022-07-21 Katleen Swinnen, Esmée Bijnens, Lidia Casas, Tim S. Nawrot, Marion Delcroix, Rozenn Quarck, Catharina Belge
We read with interest the paper by Sofianopoulou et al. [1]. The authors have significantly contributed to highlighting the potential link between air pollution and health outcomes among pulmonary arterial hypertension (PAH) patients, by showing that exposure to particulate matter with an aerodynamic diameter smaller than 2.5 µm (PM2.5) was significantly associated with transplant-free survival, and
-
The environmental impact of inhaled therapy: making informed treatment choices Eur. Respir. J. (IF 33.795) Pub Date : 2022-07-21 Ashley Woodcock, Kai M. Beeh, Hironori Sagara, Simon Aumônier, Emmanuel Addo-Yobo, Javaid Khan, Jørgen Vestbo, Helen Tope
When selecting the best inhaler and drug combination for a patient with respiratory disease, a number of factors should be considered. While efficacy and safety of medical treatments are always a priority, in recent years the environmental impacts of all aspects of life have become an increasingly necessary consideration and inhaled therapies are no exception. The carbon footprint of an item, individual
-
A randomised controlled trial of intrapleural balloon intercostal chest drains to prevent drain displacement Eur. Respir. J. (IF 33.795) Pub Date : 2022-07-21 Rachel M. Mercer, Eleanor Mishra, Radhika Banka, John P. Corcoran, Cyrus Daneshvar, Rakesh K. Panchal, Tarek Saba, Melanie Caswell, Sarah Johnstone, Daniel Menzies, Sana Ahmer, Mitra Shahidi, Amelia O. Clive, Manish Gautam, Giles Cox, Chris Orton, Judith Lyons, Nadeem Maddekar, Duneesha De Fonseka, Kathryn Prior, Simon Barnes, Grace Robinson, Louise Brown, Mohammed Munavvar, Palav L. Shah, Robert J
Background Chest drain displacement is a common clinical problem that occurs in 9–42% of cases and results in treatment failure or additional pleural procedures conferring unnecessary risk. A novel chest drain with an integrated intrapleural balloon may reduce the risk of displacement. Methods A prospective randomised controlled trial comparing the balloon drain to standard care (12 F chest drain with
-
Chronic lung allograft dysfunction phenotype and prognosis by machine learning CT analysis Eur. Respir. J. (IF 33.795) Pub Date : 2022-07-21 Micheal C. McInnis, Jin Ma, Gauri Rani Karur, Christian Houbois, Liran Levy, Jan Havlin, Eyal Fuchs, Jussi Tikkanen, Chung-Wai Chow, Ella Huszti, Tereza Martinu
Background Chronic lung allograft dysfunction (CLAD) is the principal cause of graft failure in lung transplant recipients and prognosis depends on CLAD phenotype. We used a machine learning computed tomography (CT) lung texture analysis tool at CLAD diagnosis for phenotyping and prognostication compared with radiologist scoring. Methods This retrospective study included all adult first double lung
-
Mechanical ventilation promotes lung tumour spread by modulation of cholesterol cell content Eur. Respir. J. (IF 33.795) Pub Date : 2022-07-21 Inés López-Alonso, Cecilia López-Martínez, Paula Martín-Vicente, Laura Amado-Rodríguez, Adrián González-López, Juan Mayordomo-Colunga, Cecilia del Busto, Marina Bernal, Irene Crespo, Aurora Astudillo, Miguel Arias-Guillén, Antonio Fueyo, Isaac Almendros, Jorge Otero, Héctor Sanz-Fraile, Ramón Farré, Guillermo M. Albaiceta
Background Mechanical stretch of cancer cells can alter their invasiveness. During mechanical ventilation, lungs may be exposed to an increased amount of stretch, but the consequences on lung tumours have not been explored. Methods To characterise the influence of mechanical ventilation on the behaviour of lung tumours, invasiveness assays and transcriptomic analyses were performed in cancer cell lines
-
Prevalence of adverse electrophysiologic and audiometric changes in nontuberculous mycobacterium treatment regimens. Eur. Respir. J. (IF 33.795) Pub Date : 2022-07-21 Madeline Mellett,Christina S Thornton,Leila Barss,Rachel K Lim,Dina A Fisher,Julie Jarand,Stephen K Field
-
COVID-19 follow-up programs across Europe: an ERS END-COVID CRC survey. Eur. Respir. J. (IF 33.795) Pub Date : 2022-07-21 Claudia Valenzuela,Mattia Nigro,James D Chalmers,Scott Wagers,Aujayeb Avinash,Merel E Hellemons,Judith Löffler-Ragg,Christopher E Brightling,Stefano Aliberti
-
Extracorporeal life support as a bridge to lung transplantation strategy in anti-MDA5+ rapidly progressive interstitial lung disease is life-saving but with persistent difficulties at the bedside Eur. Respir. J. (IF 33.795) Pub Date : 2022-07-13 Cloé Comarmond, Bruno Mégarbane
In a recent issue of the European Respiratory Journal, Bay et al. [1] reported 15 patients with anti-melanoma differentiation-associated protein 5 (anti-MDA5+) rapidly progressive interstitial lung disease (RP-ILD) requiring extracorporeal life support (ECLS). In five patients, ECLS implementation allowing a bridge to emergency lung transplantation within a median delay of 8 days led to survival whereas